Have you ever wondered what makes a microbiology laboratory instrument efficient? Efficiency comes from flexible, ergonomically designed instruments and software that enable effective process control and information flow – all with minimal user interaction.
These principles were the driving force behind the latest software update for bioMérieux’s VITEK® 2 instrument for automated identification and antimicrobial susceptibility testing (ID/AST). VITEK® 2 is considered the most efficient ID/AST system on the market with automated, standardized, same-day results1-6 and the shortest sample preparation time in the industry2,7-11.
Now, with the launch of VITEK® 2 Systems 8.01 software, users will be able to make even more effective use of their systems. The intuitive, secure, web-based, customizable software helps streamline lab workflow with multi-user access from virtually anywhere, anytime. This software update is an opportunity for lab managers to rethink lab workflow, promoting more efficient and timely sample preparation. VITEK® 2 Systems 8.01 software lets users:
- Set up ID and AST cards remotely from any web-enabled computer without the Smart Carrier Station
- Enjoy simultaneous, customizable setup of multiple cassettes
- Review and approve isolate and patient information from any web-enabled PC
In addition, VITEK® 2 systems 8.01 software will also be able to run cards containing the new antibiotic, ceftolozane/tazobactam. This antimicrobial enables determination of antimicrobial susceptibility to ceftolozane/tazobactam of Gram negative aerobic bacteria such as Enterobacteriaceae and P. aeruginosa. This helps optimize treatment with Zerbaxa®, by Merck.
|Ceftolozane from Merck is a new cephalosporin that inhibits the PBPs of P. aeruginosa(e.g., PBP1b, PBP1c and PBP3) and E. coli (e.g., PBP3). When combined with the beta-lactamase inhibitor tazobactam, in vitro activity against Enterobacteriaceae has been demonstrated with some ESBLs (TEM, SHV, CTX-M and OXA). The combination has also demonstrated in vitro activity against P. aeruginosa with chromosomal AmpC, OprD, MexXY and MexAB. For more information on ceftolozane/tazobactam, please visit the following website: https://www.zerbaxa.com/|
Please contact your local bioMérieux representative to discuss timelines for a software update to VITEK® 2 Systems 8.01 software.
Table1: New Microorganisms Available with VITEK® 2 Systems 8.01
|Hafnia paralvei||Streptococcus iniae|
|Tatumella ptyseos||Listeria rocourtiae|
|Ralstonia insidiosa||Listeria fleischmannii|
|Riemerella anatipestifer||Cryptococcus gattii|
|Histophilus somni||Zygosaccharomyces spp|
|Actinobacillus pleuropneumoniae||Candida auris|
|Actinobacillus suis||Candida duobushaemulonii|
|Moraxella (Neisseria) ovis||Candida haemulonii var vulnera|
Barry J., Brown A., Ensor V., Lakhani U., Petts D., Warren C., Winstanley T. Comparative evaluation of the VITEK® 2 Advanced Expert System (AES) in five UK hospitals. Journal of Antimicrobial Chemotherapy, 2003; 51: 1191–1202.
Blondel-Hill E., Jang W., Lee I., Borton N., Book L., Thomas E. Comparison of Phoenix™ and VITEK® 2 Compact for Performance of Identification and Susceptibility Testing, Workflow, and Time to Report. ICAAC 2006; Poster D-691.
Barenfanger J., et. al. J Clin Microbiol, 1999; 37(5): 1415
Galar A., Yuste J.R., Espinosa M., Guillén-Grima F., Hernáez-Crespo S., and Leiva J. Clinical and economic impact of rapid reporting of bacterial identification and antimicrobial susceptibility results of the most frequently processed specimen types. Eur J Clin Microbiol Infect Dis, 2012; 31 (9): 2445-2452.
Galar A., et. al. J Infect, 2012; 65(4):302
LaBombardi V.J. Maximizing the Use of the Advanced Expert System™ to Improve Patient Care. bioMerieux White Paper, 2011.
Ayats J., Cisnal M., Lucena J., and Marin R. Analysis of the Impact of Using a VITEK® 2 COMPACT System in a Clinical Microbiology Laboratory: Comparison with the MicroScan WalkAway System®. ASM 2007; Poster C-158.
Eigner U., Schmid A., Wild U., Bertsch D., Fahr A.M. Analysis of the Comparative Workflow and Performance Characteristics of the VITEK 2 and Phoenix Systems. Journal of Clinical Microbiology, 2005; 43(8): 3829–3834.
Heller-Ono A. Ergonomic Analysis Comparison of the VITEK® 2 and VITEK® 2 Compact with the Microscan WalkAway® 96 and Phoenix™ For Work Flow Efficiency and the Likelihood of Distal Upper Extremity Strain. bioMerieux White Paper, 2008.
Hooper M., Hill C., Hadwell V., Blondel-Hill E. Comparison of bioMerieux VITEK® 2 XL, BD Phoenix, and Seimens MicroScan Walkaway96 plus choosing an identification and antimicrobial susceptibility testing system for a medium sized microbiology laboratory. ECCMID 2013; Poster P-1536.
Römmler W., Beer L., Kessler M., and Kaehler K. Analysis of the Comparative Workflow and ID/ AST Test Result Accuracy of the VITEK® 2 compact and the Phoenix™ Systems. ASM 2006; Poster C-123.